Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Current Deferred Revenue (2016 - 2025)

Macrogenics (MGNX) has disclosed Current Deferred Revenue for 14 consecutive years, with $10.9 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 33.08% to $10.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.9 million through Dec 2025, down 33.08% year-over-year, with the annual reading at $10.9 million for FY2025, 33.08% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $10.9 million at Macrogenics, up from $10.3 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $100.0 million in Q1 2023, with the low at $3.5 million in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $19.6 million, with a median of $16.3 million recorded in 2021.
  • The sharpest move saw Current Deferred Revenue soared 626.19% in 2022, then crashed 77.16% in 2024.
  • Over 5 years, Current Deferred Revenue stood at $20.6 million in 2021, then crashed by 51.62% to $10.0 million in 2022, then soared by 116.77% to $21.7 million in 2023, then fell by 24.63% to $16.3 million in 2024, then tumbled by 33.08% to $10.9 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $10.9 million, $10.3 million, and $7.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.